Randomized trial of Covid-19 chemoprophylaxis in healthcare professionals (COVIDAXIS trial)
- Funded by Institut Pasteur International Network (IPIN)
- Total publications:0 publications
Grant number: COVIDAXIS trial
Grant search
Key facts
Disease
COVID-19Funder
Institut Pasteur International Network (IPIN)Principal Investigator
N/A
Research Location
FranceLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Clinical trials for disease management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Randomized Controlled Trial
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Hospital personnelUnspecified
Abstract
Objective: To determine whether a two months treatment with hydroxychloroquine (HCQ) or Lopinavir / ritonavir (LPV / r) reduces the incidence of symptomatic or asymptomatic infections with SARS-CoV-2, compared to their placebo, in healthcare professionals exposed to the virus.In the absence of specific antiviral treatment, particular attention must be paid to prevention. Individual protective equipment can be insufficiently protective, including for healthcare professionals.If this trial confirms the efficacy of either drug, a chemoprophylaxis strategy could be extended to other populations highly exposed to SARS-CoV-2 or at risk of severe forms of Covid-19 while waiting for other preventive tools, vaccines in particular, to become available.